Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
This 8-week, open-label extension of a double-blind study reports on safety data for 171 adolescents with attention-deficit/hyperactivity disorder (ADHD) who received once-daily OROS methylphenidate (MPH) (18-72 mg/day). Headache, anorexia, and insomnia were the most frequently reported treatment-related adverse events. The incidence of adverse events was not related to dose. OROS MPH was safe and well tolerated at doses up to 72 mg/day.
McGough
James J
JJ
Semel Institute for Neuroscience and Human Behavior, and David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Los Angeles, CA 90095, USA. jmcgough@mednet.ucla.edu
McBurnett
Keith
K
Bukstein
Oscar
O
Wilens
Timothy E
TE
Greenhill
Laurence
L
Lerner
Marc
M
Stein
Mark
M
D000293:Adolescent; D000855:Anorexia / Q000139:chemically induced; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008774:Methylphenidate / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D015431:Weight Loss
D000697:Central Nervous System Stimulants; D008774:Methylphenidate